<DOC>
	<DOCNO>NCT00003432</DOCNO>
	<brief_summary>RATIONALE : Immunotherapy use CEA-treated white blood cell may help person 's body build immune response kill tumor cell . PURPOSE : Phase I/II trial study effectiveness immunotherapy CEA-treated white blood cell treat patient metastatic breast cancer achieve partial complete response chemotherapy peripheral stem cell transplantation .</brief_summary>
	<brief_title>Immunotherapy Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate ability active immunotherapy carcinoembryonic antigen ( CEA ) RNA pulse dendritic cell induce CEA specific T cell patient metastatic breast cancer complete remission follow peripheral blood stem cell transplant . - Determine clinical efficacy term overall recurrence free survival immunotherapy CEA RNA pulse dendritic cell patient population . OUTLINE : Dendritic cell take leukapheresis product obtain peripheral blood stem cell transplant procedure perform prior treatment study . The dendritic cell pulse carcinoembryonic antigen ( CEA ) RNA . Approximately 60-90 day peripheral blood stem cell transplant , patient receive CEA RNA pulse dendritic cell IV every 3 week total 4 dos . Patients undergo second leukopheresis last dose immunotherapy obtain specimens immunologic test . Patients follow every 3 month first year annually thereafter . PROJECTED ACCRUAL : A total 14-26 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic breast cancer express carcinoembryonic antigen ( CEA ) At least 25 % tumor cell must stain positive CEA least moderate intensity Must achieve either partial response complete response high dose chemotherapy peripheral blood stem cell transplant Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Menopausal status : Not specify Performance status : Karnofsky 70100 % Life expectancy : Greater 6 month Hematopoietic : Absolute neutrophil count least 1000/mm^3 Absolute lymphocyte count least 1000/mm^3 Hemoglobin least 9 mg/dL Platelet count least 100,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL No serious ongoing chronic acute hepatic disease Renal : Creatinine le 2.5 mg/dL Cardiovascular : No serious ongoing chronic acute cardiac disease ( New York Heart Association class III IV ) Pulmonary : No serious ongoing chronic acute pulmonary illness asthma , chronic obstructive pulmonary disease , radiation drug induce pneumonitis Other : No prior concurrent malignancy except nonmelanoma skin cancer control superficial bladder cancer within past 5 year No history autoimmune disease inflammatory bowel disease , systemic lupus erythematosus , rheumatoid arthritis , ankylose spondylitis , scleroderma , multiple sclerosis No inflammatory bowel condition active infectious enteritis eosinophilic enteritis No active acute chronic infection urinary tract infection , HIV , viral hepatitis Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No concurrent immunotherapy Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : At least 4 week since steroid No concurrent steroid therapy Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : No concurrent immunosuppressive agent azathioprine cyclosporine A</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
</DOC>